Molecular Profile | MPL W515L |
Therapy | BEZ235 + Ruxolitinib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Create By | tyin |
Update By | tyin |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | MPL W515L | Advanced Solid Tumor | sensitive | BEZ235 + Ruxolitinib | Preclinical | Actionable | In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790). | 24251790 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(24251790) | Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. | Full reference... |